Skip to main content
NCBI home page
Thorax logoLink to Thorax
. 1989 Dec;44(12):1038–1044. doi: 10.1136/thx.44.12.1038

Prevention of lung infections associated with human immunodeficiency virus infection.

P C Hopewell 1
PMCID: PMC1020882  PMID: 2575801

Abstract

Current evidence indicates that the length of survival for patients with the acquired immunodeficiency syndrome (AIDS) is increasing, thereby affording a greater opportunity for strategies designed to prevent the infectious diseases that mark the syndrome. Because these infections may occur at different stages of immunosuppression caused by the human immunodeficiency virus (HIV), effective application of preventive measures depends not only on detection of HIV infection but also on the use of staging indicators. The diseases that serve to define AIDS, such as Pneumocystis carinii pneumonia, tend to occur late in the course of HIV infection and often when the T helper lymphocyte (CD4+ cells) count is less than 0.2 x 10(9)/l. Other infections, such as tuberculosis and pyogenic bacterial pneumonia, may develop at any point after HIV infection has occurred. Given this relation between the degree of immunosuppression and the occurrence of particular pulmonary infections, different preventive interventions should be applied at different times. It is now known that the incidence of several of the pulmonary infections that are common in patients with HIV infection can be reduced by prophylactic measures. Pneumocystis pneumonia is decreased in frequency by any one of several prophylactic agents, the best established being pentamidine administered as an inhaled aerosol. The role of isoniazid in the chemoprophylaxis of tuberculosis in patients not infected with HIV is well established. Although there is little evidence of benefit so far from isoniazid in HIV infected patients with a positive tuberculin skin test response, it is logical to assume that there could be some effect. The use of pneumococcal polysaccharide vaccine may also be of some benefit in reducing the frequency of pneumococcal pneumonia in patients with AIDS. In addition to these specific measures, the antiretroviral agent zidovudine decreases both the frequency and the severity of opportunist infections, at least during the first few months of treatment. A comprehensive strategy for prevention of HIV associated lung infection first requires detection of HIV seropositivity, staging the immunosuppression by the CD4+ cell count, and determining whether tuberculous infection is present by a tuberculin skin test. All seropositive individuals should be given pneumococcal vaccine and those with evidence of tuberculosis infection should be treated with isoniazid for one year. Zidovudine should probably be started when CD4+ cell counts are in the range 0.4-0.5 x 10(9)/l and prophylaxis against pneumocystis infection when CD4+ cell counts are in the range 0.2-0.3 x 10(9)/l.

Full text

PDF
1038

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ammann A. J., Schiffman G., Abrams D., Volberding P., Ziegler J., Conant M. B-cell immunodeficiency in acquired immune deficiency syndrome. JAMA. 1984 Mar 16;251(11):1447–1449. [PubMed] [Google Scholar]
  2. Centers for Disease Control (CDC) Pneumococcal polysaccharide vaccine. MMWR Morb Mortal Wkly Rep. 1989 Feb 10;38(5):64-8, 73-6. [PubMed] [Google Scholar]
  3. Chaisson R. E. Bacterial pneumonia in patients with human immunodeficiency virus infection. Semin Respir Infect. 1989 Jun;4(2):133–138. [PubMed] [Google Scholar]
  4. Chaisson R. E., Schecter G. F., Theuer C. P., Rutherford G. W., Echenberg D. F., Hopewell P. C. Tuberculosis in patients with the acquired immunodeficiency syndrome. Clinical features, response to therapy, and survival. Am Rev Respir Dis. 1987 Sep;136(3):570–574. doi: 10.1164/ajrccm/136.3.570. [DOI] [PubMed] [Google Scholar]
  5. Eyster M. E., Gail M. H., Ballard J. O., Al-Mondhiry H., Goedert J. J. Natural history of human immunodeficiency virus infections in hemophiliacs: effects of T-cell subsets, platelet counts, and age. Ann Intern Med. 1987 Jul;107(1):1–6. doi: 10.7326/0003-4819-107-1-1. [DOI] [PubMed] [Google Scholar]
  6. Ferebee S. H. Controlled chemoprophylaxis trials in tuberculosis. A general review. Bibl Tuberc. 1970;26:28–106. [PubMed] [Google Scholar]
  7. Fischl M. A., Dickinson G. M. Fansidar prophylaxis of Pneumocystis pneumonia in the acquired immunodeficiency syndrome. Ann Intern Med. 1986 Oct;105(4):629–629. doi: 10.7326/0003-4819-105-4-629_1. [DOI] [PubMed] [Google Scholar]
  8. Fischl M. A., Dickinson G. M., La Voie L. Safety and efficacy of sulfamethoxazole and trimethoprim chemoprophylaxis for Pneumocystis carinii pneumonia in AIDS. JAMA. 1988 Feb 26;259(8):1185–1189. doi: 10.1001/jama.259.8.1185. [DOI] [PubMed] [Google Scholar]
  9. Fischl M. A., Richman D. D., Grieco M. H., Gottlieb M. S., Volberding P. A., Laskin O. L., Leedom J. M., Groopman J. E., Mildvan D., Schooley R. T. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med. 1987 Jul 23;317(4):185–191. doi: 10.1056/NEJM198707233170401. [DOI] [PubMed] [Google Scholar]
  10. Hopewell P. C. Tuberculosis and human immunodeficiency virus infection. Semin Respir Infect. 1989 Jun;4(2):111–122. [PubMed] [Google Scholar]
  11. Huang K. L., Ruben F. L., Rinaldo C. R., Jr, Kingsley L., Lyter D. W., Ho M. Antibody responses after influenza and pneumococcal immunization in HIV-infected homosexual men. JAMA. 1987 Apr 17;257(15):2047–2050. [PubMed] [Google Scholar]
  12. Hughes W. T., Kuhn S., Chaudhary S., Feldman S., Verzosa M., Aur R. J., Pratt C., George S. L. Successful chemoprophylaxis for Pneumocystis carinii pneumonitis. N Engl J Med. 1977 Dec 29;297(26):1419–1426. doi: 10.1056/NEJM197712292972602. [DOI] [PubMed] [Google Scholar]
  13. Kavesh N. G., Holzman R. S., Seidlin M. The combined toxicity of azidothymidine and antimycobacterial agents. A retrospective study. Am Rev Respir Dis. 1989 May;139(5):1094–1097. doi: 10.1164/ajrccm/139.5.1094. [DOI] [PubMed] [Google Scholar]
  14. Masur H., Ognibene F. P., Yarchoan R., Shelhamer J. H., Baird B. F., Travis W., Suffredini A. F., Deyton L., Kovacs J. A., Falloon J. CD4 counts as predictors of opportunistic pneumonias in human immunodeficiency virus (HIV) infection. Ann Intern Med. 1989 Aug 1;111(3):223–231. doi: 10.7326/0003-4819-111-3-223. [DOI] [PubMed] [Google Scholar]
  15. Montgomery A. B., Debs R. J., Luce J. M., Corkery K. J., Turner J., Hopewell P. C. Aerosolized pentamidine as second line therapy in patients with AIDS and Pneumocystis carinii pneumonia. Chest. 1989 Apr;95(4):747–750. doi: 10.1378/chest.95.4.747. [DOI] [PubMed] [Google Scholar]
  16. Montgomery A. B. Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome: pathophysiology, therapy, and prevention. Semin Respir Infect. 1989 Jun;4(2):102–110. [PubMed] [Google Scholar]
  17. Moss A. R., Bacchetti P., Osmond D., Krampf W., Chaisson R. E., Stites D., Wilber J., Allain J. P., Carlson J. Seropositivity for HIV and the development of AIDS or AIDS related condition: three year follow up of the San Francisco General Hospital cohort. Br Med J (Clin Res Ed) 1988 Mar 12;296(6624):745–750. doi: 10.1136/bmj.296.6624.745. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Richman D. D., Fischl M. A., Grieco M. H., Gottlieb M. S., Volberding P. A., Laskin O. L., Leedom J. M., Groopman J. E., Mildvan D., Hirsch M. S. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med. 1987 Jul 23;317(4):192–197. doi: 10.1056/NEJM198707233170402. [DOI] [PubMed] [Google Scholar]
  19. Rothenberg R., Woelfel M., Stoneburner R., Milberg J., Parker R., Truman B. Survival with the acquired immunodeficiency syndrome. Experience with 5833 cases in New York City. N Engl J Med. 1987 Nov 19;317(21):1297–1302. doi: 10.1056/NEJM198711193172101. [DOI] [PubMed] [Google Scholar]
  20. Selwyn P. A., Feingold A. R., Hartel D., Schoenbaum E. E., Alderman M. H., Klein R. S., Friedland G. H. Increased risk of bacterial pneumonia in HIV-infected intravenous drug users without AIDS. AIDS. 1988 Aug;2(4):267–272. doi: 10.1097/00002030-198808000-00005. [DOI] [PubMed] [Google Scholar]
  21. Selwyn P. A., Hartel D., Lewis V. A., Schoenbaum E. E., Vermund S. H., Klein R. S., Walker A. T., Friedland G. H. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med. 1989 Mar 2;320(9):545–550. doi: 10.1056/NEJM198903023200901. [DOI] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES